Aude Thibaut is a co-Founder of Sonic Womb, a medical science R&D venture and collaboration with University College London studying acoustic properties in utero in order to improve neonatal environments for premature babies. She is also an angel of BioSelf’s Sensate, a wellbeing device that stimulates the vagal nerve for profound relaxation. She sits on the investment committee of the Innovation Fund, a Brussels-based investor in early-stage chemicals and life sciences start-ups.

Daniel Mansson is CEO & Founder of Flow Neuroscience. Daniel is passionate about changing the way the world views and treats mental health.

As a Clinical psychologist with a BSc in Computer Science, he has made it his mission to develop innovative solutions to treat mental health across the world. As a result of his ethos, he co-founded Flow Neuroscience, a neurotech company with a focus on empowerment, accessibility and compassion. The first product born from this was Flow, the only medically-certified device to treat Major Depressive Disorder combining brain stimulation with behavioural therapy.

Personally, Daniel wants to normalise conversations towards mental health, inspire young people to innovate and question traditional methods to build more safe and accessible tools.

Dr Elan Schneider, DPT, MSPT, CYT, is CEO & Co-Founder Train Pain, Israel and is a physical therapist specializing in neuro-rehabilitation of chronic pain.

Elan has over a decade of experience as a clinician and clinical director. He has delivered advanced clinical training to hundreds of health care professionals and has lectured internationally on the topic of chronic pain science and rehabilitation.

Elan co-founded the Retrain Pain Foundation, a non-profit organization dedicated to pain education, and has created courses used in pain clinics throughout the world including the U.K.’s NHS and U.S. Veterans Affairs pain clinics. Elan is also the co-founder of TrainPain – a digital health company developing a novel technology for the treatment of chronic pain.

Elan is optimistic about the future of pain treatment. He is a passionate advocate for public awareness of modern pain science, and its implications on policy, health care systems change and improved patient-centred care.

Professor David Wilkinson obtained postgraduate degrees in experimental psychology and neurological science from the University of Kent and University College London respectively, before completing post-doctoral fellowships at the University of Oxford and Harvard Medical School. Since moving back to Kent in 2005, his research group has focused on understanding how the workings of the human balance system affect general brain health. The group has developed clinically approved non-invasive methods of stimulating the balance organs of the inner ear with electric and thermal currents to treat symptoms of Neuro-disability associated with stroke, traumatic brain injury, migraine and, most recently, Parkinson’s disease. This latter work has culminated in plans for the world’s first clinical, education and research centre for the non-invasive treatment of Parkinson’s disease (see https://www.kent.ac.uk/parkinsons) which (provided the fund-raising target is reached) will open early next year in partnership with the charity Parkinson’s Care and Support UK.

Aside from his research activity, Professor Wilkinson is a former Director of the South East Research Design Service, National Institute for Health Research, and is currently Director of the Division of Human and Social Sciences at the University of Kent.